This study has identified GSTO1-1 as a novel target for the development of drugs for the treatment of inflammation mediated via TLR4 and possibly the treatment of the inflammation associated with obesity. Here, GSTO1 is linked to obesity due to melanocortin 4 receptor deficiency.